Sintilimab
2021-TJ-OCCC
Phase 2 small_molecule completed
Quick answer
Sintilimab for Ovarian Clear Cell Carcinoma is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Ovarian Clear Cell Carcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed